Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response

Oncogene

Volumn 29, Issue 33, 2010, Pages 4715-4724

  Weiss, M B ^a,b   Vitolo, M I ^a   Mohseni, M ^c   Rosen, D M ^d   Denmeade, S R ^d   Park, B H ^d   Weber, D J ^a,e   Bachman, K E ^a,e  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

chromosomal instability; Doxorubicin; MCF 10A; p53; TP53

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR; FLUOROURACIL; NEOMYCIN; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER INVASION; CELL CYCLE; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; DNA DAMAGE; DRUG RESISTANCE; DRUG SENSITIVITY; GENE DELETION; GENE INACTIVATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; BREAST; BREAST NEOPLASMS; CELL GROWTH; CELL LINE; CELL TRANSFORMATION; EPITHELIUM CELL; FEMALE; GENETICS; MAMMARY GLAND; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

ANIMALS; BREAST; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMAL INSTABILITY; DOXORUBICIN; EPITHELIAL CELLS; FEMALE; GENE KNOCKOUT TECHNIQUES; GENES, P53; HUMANS; MAMMARY GLANDS, HUMAN; MICE; MICE, NUDE;

EID: 77955921532     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.220     Document Type: Article

References (49)

1. Meta-analysis group in cancer (1998). Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301-308.
2. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE et al. (1996). Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811-814.
3. Agarwal ML, Agarwal A, Taylor WR, Stark GR. (1995). p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 92: 8493-8497.
4. Bachman KE, Blair BG, Brenner K, Bardelli A, Arena S, Zhou S et al. (2004). p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther 3: 221-225.
5. Bischoff FZ, Yim SO, Pathak S, Grant G, Siciliano MJ, Giovanella BC et al. (1990). Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization. Cancer Res 50: 7979-7984.
6. Bomme L, Lothe RA, Bardi G, Fenger C, Kronborg O, Heim S. (2001). Assessments of clonal composition of colorectal adenomas by FISH analysis of chromosomes 1, 7, 13 and 20. Int J Cancer 92: 816-823.
7. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP et al. (1998). Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501.
8. Bunz F, Fauth C, Speicher MR, Dutriaux A, Sedivy JM, Kinzler KW et al. (2002). Targeted inactivation of p53 in human cells does not result in aneuploidy. Cancer Res 62: 1129-1133.
9. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L et al. (1999). Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104: 263-269.
10. Calistri D, Rengucci C, Seymour I, Leonardi E, Truini M, Malacarne D et al. (2006). KRAS, p53 and BRAF gene mutations and aneuploidy in sporadic colorectal cancer progression. Cell Oncol 28: 161-166.
11. Campomenosi P, Assereto P, Bogliolo M, Fronza G, Abbondandolo A, Capasso A et al. (1998). p53 mutations and DNA ploidy in colorectal adenocarcinomas. Anal Cell Pathol 17: 1-12.
12. Chiba S, Okuda M, Mussman JG, Fukasawa K. (2000). Genomic convergence and suppression of centrosome hyperamplification in primary p53\/\cells in prolonged culture. Exp Cell Res 258: 310-321.
13. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ et al. (2003). Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21: 1431-1439.
14. Dutt A, Beroukhim R. (2007). Single nucleotide polymorphism array analysis of cancer. Curr Opin Oncol 19: 43-49.
15. El-Deiry WS. (1998). Regulation of p53 downstream genes. Semin Cancer Biol 8: 345-357.
16. Formenti SC, Dunnington G, Uzieli B, Lenz H, Keren-Rosenberg S, Silberman H et al. (1997). Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy. Int J Radiat Oncol Biol Phys 39: 1059-1068.
17. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF. (1996). Abnormal centrosome amplification in the absence of p53. Science 271: 1744-1747.
18. Fukasawa K, Wiener F, Vande Woude GF, Mai S. (1997). Genomic instability and apoptosis are frequent in p53 deficient young mice. Oncogene 15: 1295-1302.
19. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878.
20. Greshock J, Feng B, Nogueira C, Ivanova E, Perna I, Nathanson K et al. (2007). A comparison of DNA copy number profiling platforms. Cancer Res 67: 10173-10180.
21. Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP et al. (2009). Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci USA 106: 2835-2840.
22. Harvey M, McArthur MJ, Montgomery Jr. CA, Butel JS, Bradley A, Donehower LA. (1993). Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet 5: 225-229.
23. Hollstein M, Sidransky D, Vogelstein B, Harris CC. (1991). p53 mutations in human cancers. Science 253: 49-53.
24. Horn HF, Vousden KH. (2007). Coping with stress: multiple ways to activate p53. Oncogene 26: 1306-1316.
25. Hyman E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S, Rozenblum E et al. (2002). Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res 62: 6240-6245.
26. Janus F, Albrechtsen N, Dornreiter I, Wiesmuller L, Grosse F, Deppert W. (1999). The dual role model for p53 in maintaining genomic integrity. Cell Mol Life Sci 55: 12-27.
27. Konishi H, Karakas B, Abukhdeir AM, Lauring J, Gustin JP, Garay JP et al. (2007). Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation. Cancer Res 67: 8460-8467.
28. Korn WM, Yasutake T, Kuo WL, Warren RS, Collins C, Tomita M et al. (1999). Chromosome arm 20q gains and other genomic alterations in colorectal cancer metastatic to liver, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Genes Chromosomes Cancer 25: 82-90.
29. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. (1992). Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491-7495.
30. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C. (2004). dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 20: 1233-1240.
31. Lothe RA, Fossli T, Danielsen HE, Stenwig AE, Nesland JM, Gallie B et al. (1992). Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors. J Natl Cancer Inst 84: 1100-1108.
32. Malkin D, Li FP, Strong LC, Fraumeni Jr. JF, Nelson CE, Kim DH et al. (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238.
33. Moon A, Kim MS, Kim TG, Kim SH, Kim HE, Chen YQ et al. (2000). H-ras, but not N-ras, induces an invasive phenotype in human breast epithelial cells: a role for MMP-2 in the H-ras-induced invasive phenotype. Int J Cancer 85: 176-181.
34. Narayan S, Jaiswal AS, Kang D, Srivastava P, Das GM, Gairola CG. (2004). Cigarette smoke condensate-induced transformation of normal human breast epithelial cells in vitro. Oncogene 23: 5880-5889.
35. Papa V, Milazzo G, Goldfine ID, Waldman FM, Vigneri R. (1997). Sporadic amplification of the insulin receptor gene in human breast cancer. J Endocrinol Invest 20: 531-536.
36. Park BH, Vogelstein B, Kinzler KW. (2001). Genetic disruption of PPAR delta decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA 98: 2598-2603.
37. Park JT, Li M, Nakayama K, Mao TL, Davidson B, Zhang Z et al. (2006). Notch3 gene amplification in ovarian cancer. Cancer Res 66: 6312-6318.
38. Pollack JR., Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE et al. (2002). Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 99: 12963-12968.
39. Riley T, Sontag E, Chen P, Levine A. (2008). Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9: 402-412.
40. Rozan S, Vincent-Salomon A, Zafrani B, Validire P, De Cremoux P, Bernoux A et al. (1998). No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 79: 27-33.
41. Sengelov L, Horn T, Steven K. (1997). p53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer. J Cancer Res Clin Oncol 123: 565-570.
42. Soule HD, Maloney TM, Wolman SR, Peterson Jr. WD, Brenz R, McGrath CM et al. (1990). Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50: 6075-6086.
43. Thorlacius S, Borresen AL, Eyfjord JE. (1993). Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res 53: 1637-1641.
44. Tsafrir D, Bacolod M, Selvanayagam Z, Tsafrir I, Shia J, Zeng Z et al. (2006). Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res 66: 2129-2137.
45. Varis A, van Rees B, Weterman M, Ristimaki A, Offerhaus J, Knuutila S. (2003). DNA copy number changes in young gastric cancer patients with special reference to chromosome 19. Br J Cancer 88: 1914-1919.
46. Vitolo MI, Weiss MB, Szmacinski M, Tahir K, Waldman T, Park BH et al. (2009). Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells. Cancer Res 69: 8275-8283.
47. Wallace-Brodeur RR, Lowe SW. (1999). Clinical implications of p53 mutations. Cell Mol Life Sci 55: 64-75.
48. Willmarth NE, Ethier SP. (2006). Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells. J Biol Chem 281: 37728-37737.
49. Yahanda AM, Bruner JM, Donehower LA, Morrison RS. (1995). Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas. Mol Cell Biol 15: 4249-4259.